TABLE 1.

Demographic characteristics of subjects by treatment group

Characteristic	Value for the following vaccine vector and construct at the indicated stage:
	Placebo, all stages combined	MRKAd6 trigene			MRKAd5 trigene, stage IB	MRKAd5 trivalent, stage IB	MRKAd5+6 trigene
		IA	IIA	IIIA			IIB	IIIB
Dose (vg)		0.5 × 109	0.5 × 1010	0.5 × 1011	0.5 × 1010	1.5 × 1010	1.0 × 109	1.0 × 1010
No. of subjects	26	8	8	8	8	8	40	41
Gender
No. (%) male	10 (38)	4 (50)	4 (50)	5 (62)	4 (50)	3 (38)	20 (50)	19 (49)
No. (%) female	16 (62)	4 (50)	4 (50)	3 (38)	4 (50)	5 (62)	20 (50)	21 (51)
Age
Mean	30.1	36.3	34.6	37.3	29.9	31.3	34.8	33.9
SD	8.8	7.2	9.9	7.6	9.3	11.0	9.5	9.7
Median	26.5	37	40	37.5	28.5	26.5	37.5	31
Range	20-47	22-46	20-45	26-45	20-45	20-49	19-48	21-50
No. (%) of the following race/ethnicity:
Asian/Pacific	3 (12)	0 (0)	0 (0)	0 (0)	1 (13)	0 (0)	0 (0)	3 (7)
Black	4 (15)	1 (13)	5 (62)	0 (0)	2 (25)	2 (25)	6 (15)	7 (17)
Caucasian	18 (69)	7 (87)	3 (38)	7 (87)	4 (50)	6 (75)	30 (75)	27 (66)
Hispanic	0 (0)	0 (0)	0 (0)	1 (13)	1 (13)	0 (0)	4 (10)	2 (5)
Other	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5)